daunorubicin

Summary

Summary: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.

Top Publications

  1. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood. 2011;117:2358-65 pubmed publisher
    We conducted a multi-institutional randomized study to determine whether high-dose daunorubicin would be as effective as standard-dose idarubicin in remission-induction therapy for newly diagnosed adult patients younger than 65 years of ..
  2. Smriti -, Zou P, McHaourab H. Mapping daunorubicin-binding Sites in the ATP-binding cassette transporter MsbA using site-specific quenching by spin labels. J Biol Chem. 2009;284:13904-13 pubmed publisher
    ..In this study, we have mapped residues proximal to the daunorubicin (DNR)-binding site in MsbA using site-specific, ATP-dependent quenching of DNR intrinsic fluorescence by spin ..
  3. Oftedal L, Selheim F, Wahlsten M, Sivonen K, Døskeland S, Herfindal L. Marine benthic cyanobacteria contain apoptosis-inducing activity synergizing with daunorubicin to kill leukemia cells, but not cardiomyocytes. Mar Drugs. 2010;8:2659-72 pubmed publisher
    ..effect of LEDGF/p75 overexpressed in AML cells, acted synergistically with the anthracycline anticancer drug daunorubicin in AML cells, and protected cardiomyoblasts against the toxic effect of anthracyclines...
  4. Vasanthakumar A, Kattusamy K, Prasad R. Regulation of daunorubicin biosynthesis in Streptomyces peucetius - feed forward and feedback transcriptional control. J Basic Microbiol. 2013;53:636-44 pubmed publisher
    ..b>Daunorubicin is a chemotherapeutic agent for treatment of certain types of cancer, which is produced as a secondary ..
  5. Guo J, Zhou J, Ying X, Men Y, Li R, Zhang Y, et al. Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells. J Pharm Pharm Sci. 2010;13:136-51 pubmed
    ..In the present study, stealth liposomal daunorubicin plus tamoxifen was developed for eradicating breast cancer cells together with cancer stem cells.
  6. Wang J, Yang Y, Zhou M, Xu J, Zhang Q, Zhou R, et al. Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia. PLoS ONE. 2013;8:e60699 pubmed publisher
    To determine whether the use of idarubicin+cytarabine (IA) is more effective than the use of daunorubicin+cytarabine (DA) as induction chemotherapy for patients with newly diagnosed acute myeloid leukaemia...
  7. Lu Y, Feng Q, Cui F, Xing W, Zhang G, Yao X. Interaction of 3'-azido-3'-deamino daunorubicin with human serum albumin: investigation by fluorescence spectroscopy and molecular modeling methods. Bioorg Med Chem Lett. 2010;20:6899-904 pubmed publisher
    In this Letter, the binding of 3'-azido-3'-deamino daunorubicin (ADNR) to human serum albumin (HSA) was investigated at different temperatures by fluorescence spectroscopy at pH 7.4...
  8. Wang J, Chen B, Chen J, Cai X, Xia G, Liu R, et al. Synthesis and antitumor efficacy of daunorubicin-loaded magnetic nanoparticles. Int J Nanomedicine. 2011;6:203-11 pubmed publisher
    A promising approach to optimize the disposition of daunorubicin-loaded magnetic nanoparticles (DNR-MNPs) was developed to minimize serious side effects of systematic chemotherapy for cancer...
  9. Han W, Sun J, Feng L, Wang K, Li D, Pan Q, et al. Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells. PLoS ONE. 2011;6:e28491 pubmed publisher
    Anthracycline daunorubicin (DNR) is one of the major antitumor agents widely used in the treatment of myeloid leukemia. Unfortunately, the clinical efficacy of DNR was limited because of its cytotoxity at high dosage...

More Information

Publications66

  1. Kaspers G, Zimmermann M, Reinhardt D, Gibson B, Tamminga R, Aleinikova O, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol. 2013;31:599-607 pubmed publisher
    ..Studies suggest that liposomal daunorubicin (DNX; DaunoXome; Galen, Craigavon, United Kingdom) is effective and less cardiotoxic, which is important in ..
  2. Lichtman M. A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3. Blood Cells Mol Dis. 2013;50:119-30 pubmed publisher
    ..7days of continuous intravenous arabinosylcytosine (cytarabine) and the first 3 concurrent days of intravenous daunorubicin, given the nickname "7+3...
  3. Cui F, Hui G, Jiang X, Zhang G. Interaction of 3'-azido-3'-deamino daunorubicin with DNA: multispectroscopic and molecular modeling. Int J Biol Macromol. 2012;50:1121-6 pubmed publisher
    In this paper, 3'-azido-3'-deamino daunorubicin (ADNR) was synthesized and the interaction of ADNR and calf thymus DNA (ctDNA) was investigated for the first time by using multi-spectroscopic techniques and molecular modeling study in ..
  4. Taghdisi S, Lavaee P, Ramezani M, Abnous K. Reversible targeting and controlled release delivery of daunorubicin to cancer cells by aptamer-wrapped carbon nanotubes. Eur J Pharm Biopharm. 2011;77:200-6 pubmed publisher
    ..sgc8c aptamer (this aptamer targets leukemia biomarker protein tyrosine kinase-7) to complex between Dau (daunorubicin) and SWNT to enhance targeted delivery of Dau to acute lymphoblastic leukemia T-cells (Molt-4)...
  5. Ying X, Wen H, Yao H, Zhang Y, Tian W, Zhang L, et al. Pharmacokinetics and tissue distribution of dual-targeting daunorubicin liposomes in mice. Pharmacology. 2011;87:105-14 pubmed publisher
    ..drugs across the blood-brain barrier (BBB) to target brain tumors, we have previously developed dual-targeting daunorubicin liposomes modified with 4-aminophenyl-?-D-manno-pyranoside and transferrin molecules...
  6. Baer M, George S, Sanford B, Mrozek K, Kolitz J, Moore J, et al. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia. 2011;25:800-7 pubmed publisher
    ..secondary (n=189) acute myeloid leukemia (AML) patients ?60 years received intensified chemotherapy, including daunorubicin 60?mg/m(2) and etoposide 100?mg/m(2) during days 1, 2, 3 with cytarabine 100?mg/m(2) during days 1-7, with a ..
  7. Advani A, Tiu R, Saunthararajah Y, Maciejewski J, Copelan E, Sobecks R, et al. A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia. Leuk Res. 2010;34:1622-6 pubmed publisher
    ..We conducted a Phase 1 study of the c-kit inhibitor, imatinib mesylate (IM), in combination with cytarabine and daunorubicin (7+3) in c-kit+ relapsed AML. IM was dose escalated using a 3 by 3 design...
  8. Brunnberg U, Mohr M, Noppeney R, Dürk H, Sauerland M, Muller Tidow C, et al. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. Ann Oncol. 2012;23:990-6 pubmed publisher
    ..This randomized phase II study compared a standard combination of ara-C and daunorubicin (DNR; 7+3) versus ara-C plus gemtuzumab ozogamicin (7+GO) as the first course of induction therapy...
  9. Yun C, Chae H, Kim H, Ahn T. Doxorubicin- and daunorubicin-induced regulation of Ca2+ and H+ fluxes through human bax inhibitor-1 reconstituted into membranes. J Pharm Sci. 2012;101:1314-26 pubmed publisher
    ..We examined the effect of doxorubicin (DXR) and daunorubicin (DNR), which are clinically important anthracycline compounds, on the functional regulation of BI-1 ..
  10. Feldman E, Kolitz J, Trang J, Liboiron B, Swenson C, Chiarella M, et al. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res. 2012;36:1283-9 pubmed publisher
    Forty-eight patients received CPX-351 (liposome-encapsulated cytarabine:daunorubicin at a 5:1 molar ratio) every other day for 3 doses at 10 dose levels...
  11. Kolitz J, George S, Marcucci G, Vij R, Powell B, Allen S, et al. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010;116:1413-21 pubmed publisher
    ..assigned 302 patients to receive induction chemotherapy regimens consisting of cytosine arabinoside (Ara-C; A), daunorubicin (D), and etoposide (E), without (ADE) or with (ADEP) PSC-833 (P)...
  12. Zhang H, Jiang H, Wang H, Zhao J, Chen B, Wang X. Ultrasound mediated drug-loaded nanoparticles crossing cell membranes as a new strategy to reverse cancer multidrug resistance. J Nanosci Nanotechnol. 2011;11:1834-40 pubmed
    ..The MDR leukemia K562/A02 cells were treated with the daunorubicin (DNR)-loaded TiO2 Nps drug carrier and US exposure...
  13. Huang B, Zeng Q, Gurung A, Zhao W, Xiao Z, Li B. The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience. Med Oncol. 2012;29:2088-94 pubmed publisher
    ..The high-risk cohort receiving As(2)O(3) overcame the negative impact, yielding OS similar to that for with the low-risk patients treated with As(2)O(3)...
  14. Huseby S, Gausdal G, Keen T, Kjærland E, Krakstad C, Myhren L, et al. Cyclic AMP induces IPC leukemia cell apoptosis via CRE-and CDK-dependent Bim transcription. Cell Death Dis. 2011;2:e237 pubmed publisher
    ..predictor of the clinical efficiency of antileukemic agents, like the first-line AML anthracycline drug daunorubicin (DNR). We show here that cAMP acted synergistically with DNR to induce IPC cell death...
  15. Xiong S, Yu B, Wu J, Li H, Lee R. Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS. Biomed Pharmacother. 2011;65:2-8 pubmed publisher
    ..on L1210JF cells and assessed targeted therapeutic efficacy of folate-PEG-CHEMS anchored liposomes loading daunorubicin (F-L-DNR) in vivo. Folate-PEG-CHEMS was synthesized by a modified method...
  16. Das A, Bhadra K, Achari B, Chakraborty P, Kumar G. Interaction of aristololactam-?-D-glucoside and daunomycin with poly(A): spectroscopic and calorimetric studies. Biophys Chem. 2011;155:10-9 pubmed publisher
    ..No self-structure formation was observed in poly(A) with both daunomycin and aristololactam-?-D-glucoside suggesting the hindrance of the sugar moiety for such structural organization. ..
  17. Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz Krzemien S, Kuliczkowski K, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol. 2012;30:2441-8 pubmed publisher
    ..age 47 years (range, 17 to 60 years) were randomly assigned to receive one of three induction regimens: DA (daunorubicin plus cytarabine), DAC (DA plus cladribine), or DAF (DA plus fludarabine)...
  18. Bains O, Grigliatti T, Reid R, Riggs K. Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J Pharmacol Exp Ther. 2010;335:533-45 pubmed publisher
    Doxorubicin (DOX) and daunorubicin (DAUN) are effective anticancer drugs; however, considerable interpatient variability exists in their pharmacokinetics...
  19. Arozal W, Watanabe K, Veeraveedu P, Thandavarayan R, Harima M, Sukumaran V, et al. Beneficial effects of angiotensin II receptor blocker, olmesartan, in limiting the cardiotoxic effect of daunorubicin in rats. Free Radic Res. 2010;44:1369-77 pubmed publisher
    ..to evaluate the role of the combination of olmesartan, an angiotensin II (Ang II) receptor blocker (ARB), with daunorubicin (DNR) in reducing cardiac toxicity in rats...
  20. Chen B, Mao P, Cheng J, Gao F, Xia G, Xu W, et al. Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells. Int J Nanomedicine. 2010;5:437-44 pubmed
    ..Analysis of the reversal ratio of MDR, the concentration of daunorubicin (DNR) and the transcription of MDR1 gene and expression of P-gp in K562/A02 showed that combination of DNR with ..
  21. Bogason A, Masquelier M, Lafolie P, Skogastierna C, Paul C, Gruber A, et al. Daunorubicin metabolism in leukemic cells isolated from patients with acute myeloid leukemia. Drug Metab Lett. 2010;4:228-32 pubmed
    Anthracyclines like daunorubicin (DNR) are important drugs in the treatment of acute myeloid leukaemia (AML). In vitro studies have shown that cellular metabolism of anthracyclines could play a role in drug resistance...
  22. Wang J, Chen B, Cheng J, Cai X, Xia G, Liu R, et al. Apoptotic mechanism of human leukemia K562/A02 cells induced by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin. Int J Nanomedicine. 2011;6:1027-34 pubmed publisher
    ..was to assess the induced apoptosis of self-assembled iron oxide magnetic nanoparticles (MNPs) co-loaded with daunorubicin (DNR) and 5-bromotetrandrin (Br Tet) (DNR/Br Tet-MNPs), acting as a drug depot system for the sustained release ..
  23. Hanna A, Janczura M, Cho E, Dulhunty A, Beard N. Multiple actions of the anthracycline daunorubicin on cardiac ryanodine receptors. Mol Pharmacol. 2011;80:538-49 pubmed publisher
    Our aim was to examine the molecular basis for acute effects of the anthracycline daunorubicin on cardiac ryanodine receptor (RyR2) channels and cardiac calsequestrin (CSQ2)...
  24. Liu J, Qiu Z, Wang S, Zhou L, Zhang S. A modified double-emulsion method for the preparation of daunorubicin-loaded polymeric nanoparticle with enhanced in vitro anti-tumor activity. Biomed Mater. 2010;5:065002 pubmed publisher
    ..In order to improve the encapsulation efficiency of daunorubicin (DNR) in poly(D,L-lactic-co-glycolic acid (PLGA) and poly(D,L-lactic acid) (PDLLA) nanoparticles, we fabricated ..
  25. Borska S, Sopel M, Chmielewska M, Zabel M, Dziegiel P. Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin. Molecules. 2010;15:857-70 pubmed publisher
    ..The study aimed at determination if Q sensitizes cells resistant to daunorubicin (DB) through its effect on P-gp expression and action...
  26. Wu W, Chen B, Cheng J, Wang J, Xu W, Liu L, et al. Biocompatibility of Fe3O4/DNR magnetic nanoparticles in the treatment of hematologic malignancies. Int J Nanomedicine. 2010;5:1079-84 pubmed publisher
    ..were to assess the biocompatibility of self-assembled Fe(3)O(4) magnetic nanoparticles (MNPs) loaded with daunorubicin (DNR), ie, (Fe(3)O(4)-MNPs/DNR), and to explore their potential application in the treatment of hematologic ..
  27. Vavrova A, Popelova O, Sterba M, Jirkovsky E, Haskova P, Mertlíková Kaiserová H, et al. In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity. Arch Toxicol. 2011;85:525-35 pubmed publisher
    ..Ten-week intravenous administration of daunorubicin (DAU, 3 mg/kg weekly) to rabbits induced heart failure, which was evident from decreased left ventricular ..
  28. Arozal W, Watanabe K, Veeraveedu P, Thandavarayan R, Harima M, Sukumaran V, et al. Effect of telmisartan in limiting the cardiotoxic effect of daunorubicin in rats. J Pharm Pharmacol. 2010;62:1776-83 pubmed publisher
    ..co-treatment of telmisartan, an angiotensin (Ang II) type-1 receptor blocker, might offer protection against daunorubicin cardiotoxic properties in rats. Daunorubicin was administered at 3 mg/kg/day every other day for 12 days...
  29. Orbán E, Mezo G, Schlage P, Csík G, Kulić Z, Ansorge P, et al. In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites. Amino Acids. 2011;41:469-83 pubmed publisher
    ..III (GnRH-III; Glp-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH(2)) was employed as a targeting moiety to which daunorubicin was attached via oxime bond, either directly or by insertion of a GFLG or YRRL tetrapeptide spacer...
  30. Shi P, Zha J, Guo X, Chen F, Fan Z, Huang F, et al. Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression. Pharmacogenomics. 2013;14:17-23 pubmed publisher
    To investigate whether idarubicin in a cytarabine-based induction regimen was superior to daunorubicin in de novo acute myeloid leukemia patients expressing high MDR1...
  31. Zhong L, Shen H, Huang C, Jing H, Cao D. AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group. Toxicol Appl Pharmacol. 2011;255:40-7 pubmed publisher
    b>Daunorubicin, idarubicin, doxorubicin and epirubicin are anthracyclines widely used for the treatment of lymphoma, leukemia, and breast, lung, and liver cancers, but tumor resistance limits their clinical success...
  32. Manea M, Leurs U, Orbán E, Baranyai Z, Öhlschläger P, Marquardt A, et al. Enhanced enzymatic stability and antitumor activity of daunorubicin-GnRH-III bioconjugates modified in position 4. Bioconjug Chem. 2011;22:1320-9 pubmed publisher
    ..enzymatic stability, and antitumor activity of novel bioconjugates containing the chemotherapeutic agent daunorubicin attached through an oxime bond to various gonadotropin-releasing hormone-III (GnRH-III) derivatives...
  33. Zhang L, Yao H, Yu Y, Zhang Y, Li R, Ju R, et al. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials. 2012;33:565-82 pubmed publisher
    ..The objectives of present study were to construct a kind of mitochondrial targeting daunorubicin plus quinacrine liposomes for treating and for preventing the recurrence of breast cancer arising from the ..
  34. Krug U, Rollig C, Koschmieder A, Heinecke A, Sauerland M, Schaich M, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010;376:2000-8 pubmed publisher
    ..were treated with two courses of intensive induction chemotherapy (tioguanine, standard-dose cytarabine, and daunorubicin followed by high-dose cytarabine and mitoxantrone; or with high-dose cytarabine and mitoxantrone in the first ..
  35. Li H, Hui L, Xu W. miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Acta Biochim Biophys Sin (Shanghai). 2012;44:269-77 pubmed publisher
    ..could modulate the sensitivity of the leukemia drug-resistant cell line K562/A02 to the chemotherapeutic agent daunorubicin (DNR), and explore the mechanism of miR-181a on the DNR sensitivity of K562/A02 cells...
  36. Adamcova M, Potacova A, Popelova O, Sterba M, Mazurova Y, Aupperle H, et al. Cardiac remodeling and MMPs on the model of chronic daunorubicin-induced cardiomyopathy in rabbits. Physiol Res. 2010;59:831-6 pubmed
    ..The study was carried out in three groups of Chinchilla male rabbits: 1) daunorubicin (3 mg/kg, once weekly for 10 weeks), 2) control (saline in the same schedule), 3) daunorubicin with the ..
  37. Skribek H, Otvos R, Flaberg E, Nagy N, Markasz L, Eksborg S, et al. Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin. Exp Hematol. 2010;38:1219-30 pubmed publisher
    ..Half of the samples were sensitive to fludarabine and chlorambucil. Daunorubicin was the most potent drug. It was effective in 75 of 77 cases...
  38. Cheng J, Wang J, Chen B, Xia G, Cai X, Liu R, et al. A promising strategy for overcoming MDR in tumor by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin. Int J Nanomedicine. 2011;6:2123-31 pubmed publisher
    ..effects of chemotherapy agents, a novel chemotherapy formulation of magnetic nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin (DNR/BrTet-MNPs) was developed, and its effect on MDR leukemic cells was explored...
  39. Hartmann K, Nieto A, Wu E, Freeman W, Kim J, Chhablani J, et al. Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin. J Ocul Pharmacol Ther. 2013;29:493-500 pubmed publisher
    ..safety of an intravitreal hydrosilylated porous silicon (pSi) drug delivery system along with the payload of daunorubicin (DNR)...
  40. Manea M, Tovari J, Tejeda M, Schulcz Á, Kapuvári B, Vincze B, et al. In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice. Anticancer Drugs. 2012;23:90-7 pubmed publisher
    ..the gonadotropin-releasing hormone-III (GnRH-III) as a targeting moiety to which the chemotherapeutic agent daunorubicin (Dau) was attached through an oxime bond either directly or by inserting a GFLG tetrapeptide spacer...
  41. Lee J, Joo Y, Kim H, Bae S, Kim M, Zang D, et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood. 2011;118:3832-41 pubmed publisher
    We conducted a phase 3 randomized trial comparing 2 different doses of daunorubicin as induction chemotherapy in young adults (60 years of age or younger) with acute myeloid leukemia (AML)...
  42. Arozal W, Watanabe K, Veeraveedu P, Ma M, Thandavarayan R, Sukumaran V, et al. Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-? agonist actions. Toxicology. 2011;279:91-9 pubmed publisher
    ..However, there is limited information regarding the nephroprotective effect of ARB in daunorubicin (DNR)-induced nephrotoxicity in rats...
  43. Zhang H, Chen B, Jiang H, Wang C, Wang H, Wang X. A strategy for ZnO nanorod mediated multi-mode cancer treatment. Biomaterials. 2011;32:1906-14 pubmed publisher
    ..of this study was to investigate a new strategy of combined application of ZnO nanorods with anticancer drug daunorubicin (DNR) in photodynamic therapy (PDT)...
  44. Zhang Y, Li R, Ying X, Tian W, Yao H, Men Y, et al. Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer. Mol Pharm. 2011;8:162-75 pubmed publisher
    ..by constructing cancer cell mitochondria-specifically targeting drug-loaded liposomes, namely, mitosomal daunorubicin plus amlodipine...
  45. Krause A, Jelińska A, Cielecka Piontek J, Klawitter M, Zalewski P, Oszczapowicz I, et al. Acid-base catalysis of N-[(morpholine)methylene]daunorubicin. Drug Dev Ind Pharm. 2012;38:1024-8 pubmed publisher
    The stability of N-[(morpholine)methylene]-daunorubicin hydrochloride (MMD) was investigated in the pH range 0.44-13.54, at 313, 308, 303 and 298 K...
  46. LaRochelle O, Bertoli S, Vergez F, Sarry J, Mansat De Mas V, Dobbelstein S, et al. Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. Oncotarget. 2011;2:850-61 pubmed
    ..005) as compared to DNMT3A exon 23- patients when treated with idarubicin, whereas patients treated with daunorubicin had similar outcome regardless the DNMT3A status...
  47. Zhang H, Wang C, Chen B, Wang X. Daunorubicin-TiO2 nanocomposites as a "smart" pH-responsive drug delivery system. Int J Nanomedicine. 2012;7:235-42 pubmed publisher
    b>Daunorubicin (DNR) has a broad spectrum of anticancer activity, but is limited in clinical application due to its serious side effects...
  48. Scandura J, Roboz G, Moh M, Morawa E, Brenet F, Bose J, et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood. 2011;118:1472-80 pubmed publisher
    ..for 3, 5, or 7 days before a single, standard induction with infusional cytarabine (100 mg/m² for 7 days) and daunorubicin (60 mg/m² × 3 doses). Toxicity was similar to that of standard induction chemotherapy alone...
  49. Sauter K, Wood L, Wong J, Iordanov M, Magun B. Doxorubicin and daunorubicin induce processing and release of interleukin-1? through activation of the NLRP3 inflammasome. Cancer Biol Ther. 2011;11:1008-16 pubmed
    Anthracyclines including doxorubicin and daunorubicin are commonly used for the treatment of both hematologic and solid tumors. Dose related adverse effects often limit the effectiveness of anthracyclines in chemotherapy...
  50. Arozal W, Watanabe K, Veeraveedu P, Ma M, Thandavarayan R, Sukumaran V, et al. Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicology. 2010;274:18-26 pubmed publisher
    b>Daunorubicin (DNR) is one of the anthracycline anti-tumor agents widely used in the treatment of acute myeloid leukemia...
  51. Attar E, Johnson J, Amrein P, Lozanski G, Wadleigh M, DeAngelo D, et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013;31:923-9 pubmed publisher
    The purpose of this study was to determine remission induction frequency when bortezomib was combined with daunorubicin and cytarabine in previously untreated older adults with acute myeloid leukemia (AML) and safety of bortezomib in ..
  52. Cariño Cortés R, Alvarez Gonzalez I, Martino Roaro L, Madrigal Bujaidar E. Effect of naringin on the DNA damage induced by daunorubicin in mouse hepatocytes and cardiocytes. Biol Pharm Bull. 2010;33:697-701 pubmed
    ..in mouse hepatocytes and cardiocytes, b) to evaluate its capacity to inhibit the DNA damage induced by daunorubicin (Dau) in the same tissues, and c) to determine its capacity to trap free radicals in vitro using the 1,1-..
  53. Feldman E, Lancet J, Kolitz J, Ritchie E, Roboz G, List A, et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011;29:979-85 pubmed publisher
    ..Adverse events were consistent with cytarabine and daunorubicin treatment. Response occurred at doses as low as 32 units/m(2)...
  54. Bai H, Xu R, Cao Z, Wei D, Wang C. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett. 2011;585:402-8 pubmed publisher
    ..investigated whether miR-21 mediated resistance of the leukaemia cell line K562 to the chemotherapeutic agent daunorubicin (DNR)...
  55. Srinivasan P, Palani S, Prasad R. Daunorubicin efflux in Streptomyces peucetius modulates biosynthesis by feedback regulation. FEMS Microbiol Lett. 2010;305:18-27 pubmed publisher
    ..genes drrA and drrB encode membrane-associated proteins that function like an ABC transporter for the efflux of daunorubicin and to maintain a constant subinhibitory physiological concentration of the drug within the cell...
  56. Stock W, Johnson J, Stone R, Kolitz J, Powell B, Wetzler M, et al. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013;119:90-8 pubmed publisher
    Cancer and Leukemia Group B (CALGB) Study 19802, a phase 2 study, evaluated whether dose intensification of daunorubicin and cytarabine could improve disease-free survival (DFS) in adults with acute lymphoblastic leukemia (ALL) and ..
  57. Lim W, Tardi P, Xie X, Fan M, Huang R, Ciofani T, et al. Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts. Leuk Lymphoma. 2010;51:1536-42 pubmed publisher
    CPX-351, a liposomal formulation co-encapsulating cytarabine (Cyt) and daunorubicin (Daun), has been developed, which delivers synergistic Cyt:Daun molar ratios to bone marrow...